Skip to content

Clinical trials

Phase 2 Inflammation trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Inflammation Phase: Phase 2 Clear all

336 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20028
20034
20045
20058
20068
200714
20087
200914
20108
201110
201215
201311
201417
201512
201614
20179
201820
201913
202018
202116
202214
202319
202417
202525
202615

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed176
Terminated39
Unknown status36
Recruiting35
Active, not recruiting21
Not yet recruiting13
Withdrawn11
Suspended3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S10
Mayo Clinic5
National Heart, Lung, and Blood Institute (NHLBI)5
Novartis Pharmaceuticals5
Amgen4
AstraZeneca4
Massachusetts General Hospital4
National Eye Institute (NEI)4
National Institute of Allergy and Infectious Diseases (NIAID)4
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Inflammation336
Atherosclerosis17
Pain17
Arthritis, Rheumatoid15
Cardiovascular Diseases14
Insulin Resistance14
Diabetes Mellitus, Type 213
Alzheimer Disease12
Cognitive Dysfunction12
Diabetes Mellitus12

Trials

Showing 51 to 75 of 336. Each trial links to its page on Pharma Observatory.

236 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.